Novo Holdings A/S - 22 Jun 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role: 10%+ Owner
Signature: /s/ Peter Haahr, Chief Financial Officer of Novo Holdings A/S
Issuer symbol: N/A
Transactions as of: 22 Jun 2021
Net transactions value: +$4,999,986
Form type: 4
Filing time: 23 Jun 2021, 17:18:29 UTC
Previous filing: 22 Jun 2021
Next filing: 21 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYT	COMMON STOCK	Conversion of derivative security		+4,562,636			4,562,636	22 Jun 2021	Direct	F1
transaction	CYT	COMMON STOCK	Purchase	$4,999,986	+277,777	+6.1%	$18.00	4,840,413	22 Jun 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYT	SERIES B CONVERTIBLE PREFERRED STOCK	Conversion of derivative security		-14,000,000	-100%		0	22 Jun 2021	COMMON STOCK	4,107,017		Direct	F1
transaction	CYT	SERIES C CONVERTIBLE PREFERRED STOCK	Conversion of derivative security		-1,553,116	-100%		0	22 Jun 2021	COMMON STOCK	455,619		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of common stock, based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock, upon the completion of the Issuer's initial public offering. These shares have no expiration date.
F2	Represents a purchase from the underwriters in the Issuer's initial public offering.